Skip to main content
Karo Pharma AB logo

Karo Pharma AB — Investor Relations & Filings

Ticker · KARO ISIN · SE0007464888 LEI · 213800G54Z51LOPGTA79 ST Manufacturing
Open in API
Filings indexed 653 across all filing types
Latest filing 2009-03-27 Annual Report
Country SE Sweden
Listing ST KARO

About Karo Pharma AB

https://www.karohealthcare.com/

Karo Pharma AB, operating as Karo Healthcare, is a healthcare company that develops, markets, and sells a broad portfolio of everyday healthcare products. The company's offerings are designed to prevent illness and treat common health problems, empowering consumers to manage their daily well-being. The portfolio consists of various branded medicines and consumer healthcare products distributed through pharmacies and directly to healthcare providers. With products available in over 90 countries, the company focuses on becoming a leading force in its sector by employing a consumer-centric approach, strategic innovation, and omnichannel excellence.

Recent filings

Filing Released Lang Actions
Annual Report 2008
Annual Report Classification · 100% confidence The document is an annual report for Karo Bio for the year 2008. It contains a table of contents, a vision statement, project portfolio details, strategic collaborations, and a legal disclaimer. It is a comprehensive document covering company activity and performance for the fiscal year, fitting the definition of an Annual Report. FY 2008
2009-03-27 Swedish
Report Publication Announcement 2009
Report Publication Announcement Classification · 99% confidence The document is very short (1801 characters) and its primary function is to announce that 'THE ANNUAL REPORT FOR 2008 NOW AVAILABLE ON KARO BIO'S WEB SITE'. It explicitly states where the report can be found and how to order the printed version, but it does not contain the actual content of the Annual Report (10-K). According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating a report has been published points to a Report Publication Announcement (RPA).
2009-03-25 English
Report Publication Announcement 2009
Report Publication Announcement Classification · 99% confidence The document is a short announcement dated March 25, 2009, with the headline in Swedish: "KARO BIOS ÅRSREDOVISNING FÖR 2008 NU TILLGÄNGLIG PÅ BOLAGETS HEMSIDA" (Karo Bio's Annual Report for 2008 is now available on the company's website). The text explicitly states that the Annual Report (Årsredovisning) for 2008 is available online and describes how to obtain the printed version. According to Rule #2 (The 'MENU VS MEAL' Rule), a short document announcing the publication of a report, rather than being the report itself, should be classified as a Report Publication Announcement (RPA). Although the content relates to the Annual Report (10-K), the document's function here is purely to announce its availability.
2009-03-25 Swedish
Regulatory Filings 2009
Regulatory Filings Classification · 95% confidence The document is a press release dated February 25, 2009, announcing that data from a clinical study (EPROTIROME STUDY) has been accepted for oral presentation at the American College of Cardiology Meeting. It details the study's findings, the drug's mechanism, and provides background information on dyslipidemia treatment and the company (Karo Bio). This type of announcement, focusing on clinical trial results being presented at a conference, is a general corporate update or news release. It is not a formal regulatory filing (like 10-K, IR, or ER), nor is it a specific report like an Audit Report (AR) or a Management Discussion & Analysis (MDA). Since it is a general announcement of corporate news/progress that doesn't fit the highly specific categories (like DIRS, DIV, CAP, etc.), the most appropriate fallback category is Regulatory Filings (RNS), which often serves as a catch-all for significant, non-standard announcements released to the public/market.
2009-02-25 English
Regulatory Filings 2009
Regulatory Filings Classification · 95% confidence The document is a press release from Karo Bio dated February 25, 2009, announcing that results from a Phase IIb clinical study of their drug eprotirome have been accepted for presentation at the American College of Cardiology Meeting. It details the study's positive outcomes regarding lipid levels and safety, and discusses the drug's potential for treating high cholesterol and cardiovascular risk factors. This content—announcing clinical trial results and providing context on the drug's potential market—is characteristic of an Earnings Release (ER) or a general announcement related to investor information, but it is not a formal regulatory filing like a 10-K or IR. Since it is an initial announcement of key financial/clinical performance highlights (the study results), the most appropriate classification is Earnings Release (ER), as it serves to inform the market of significant operational/development milestones that impact valuation, similar to quarterly earnings. It is not a Call Transcript (CT), a full Interim Report (IR), or a presentation (IP). It is an announcement of results, fitting the ER definition best.
2009-02-25 Swedish
Interim / Quarterly Report 2008
Interim / Quarterly Report Classification · 100% confidence The document is a 'Bokslutsrapport' (Year-end report) for the period January-December 2008, containing comprehensive financial statements, management commentary, and operational updates. It provides detailed financial data (income statement, cash flow, balance sheet items) for the full fiscal year and the fourth quarter. It is not a mere announcement (RPA) as it contains the full financial results and analysis. Therefore, it is classified as an Interim/Quarterly Report (IR) as it covers a specific reporting period and includes substantive financial data. FY 2008
2009-02-06 Swedish

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.